ArticleInternational wound journal2017
From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases.
Article in International wound journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Protease activity as a prognostic factor for wound healing in venous leg ulcers.The Cochrane database of systematic reviews · 2018Pooled it
- Skin tears and risk factors assessment: a systematic review on evidence-based medicine.International wound journal · 2018Pooled it
- Glycocalyx disruption, endothelial dysfunction and vascular remodeling as underlying mechanisms and treatment targets of chronic venous disease.International angiology : a journal of the International Union of Angiology · 2024Review
- Matrix Metalloproteinases in Health and Disease 3.0.Biomolecules · 2024Article
- Research progress on and molecular mechanism of vacuum sealing drainage in the treatment of diabetic foot ulcers.Frontiers in surgery · 2024Review
- Stasis Dermatitis: Pathophysiology, Current Treatment Paradigms, and the Use of the Flavonoid Diosmin.The Journal of clinical and aesthetic dermatology · 2024Review
- Risk Factors for Bleeding Varicose Veins in Patients with Chronic Venous Disease.Medicina (Kaunas, Lithuania) · 2023Article
- Metalloproteases in Pain Generation and Persistence: A Possible Target?Biomolecules · 2023Review
- Molecular Determinants of Chronic Venous Disease: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Wound Healing versus Metastasis: Role of Oxidative Stress.Biomedicines · 2022Review
- Detection of interstitial pneumonia with autoimmune features and idiopathic pulmonary fibrosis are enhanced by involvement of matrix metalloproteinases levels and clinical diagnosis.Journal of clinical laboratory analysis · 2022Article
- Matrix Metalloproteinases in Health and Disease 2.0.Biomolecules · 2022Article
- Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.Vessel plus · 2021Article
- Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment.Journal of clinical medicine · 2020Review
- Matrix Metalloproteinases in Health and Disease.Biomolecules · 2020Article
- Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.International journal of molecular sciences · 2020Review
- Local release of metalloproteinases and their inhibitors after a successful revascularisation procedure.International wound journal · 2020Article
- Precision Medicine and Precision Nursing: The Era of Biomarkers and Precision Health.International journal of general medicine · 2020Review
- CGF Treatment of Leg Ulcers: a Randomized Controlled Trial.Open medicine (Warsaw, Poland) · 2019Article
- Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.Advances in pharmacology (San Diego, Calif.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic venous disease (CVD) and its most frightening complication, chronic venous ulceration (CVU), represent an important socioeconomic burden in the western world. Metalloproteinases have been identified in the pathogenesis of several vascular diseases such as venous problems. The aim of this study was to evaluate a broad range of metalloproteinases, such as matrix metalloproteinases (MMPs), ADAMs (a disintegrin and metalloproteinases) and ADAMTSs (a disintegrin and metalloproteinases with thrombospondin motifs) and their inhibitors, tissue inhibitor of metalloproteinases (TIMPs) and a related protein, neutrophil gelatinase-associated lipocalin (NGAL), in patients with CVD in order to correlate their serum levels with each stage of the disease. We performed a multicenter open-label study that comprised the enrolment of 541 patients with CVD of clinical stages C1-C6, (178 males, 363 females; mean age 57·29, median age 53·72, age range 29-81); 29 subjects without CVD were included in this study (9 males and 20 females; mean age 54·44, median age 50, age range 28-84) as the control group. Enzyme-linked immunosorbent assay (ELISA) was performed for measuring serum levels of proteases and related proteins. The study found that the serum elevation of MMP-2, ADAMTS-1 and ADAMTS-7 appeared to be correlated with the initial stages of CVD, whereas the serum elevation of MMP-1, MMP-8, MMP-9, NGAL, ADAM-10, ADAM-17 and ADAMTS-4 was particularly involved in skin change complications. This study showed that each stage of CVD may be described by particular patterns of metalloproteinases, and this may have therapeutic implications in discovering new targets and new drugs for the treatment of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.